OraPharma, Inc.
http://www.orapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OraPharma, Inc.
Deals Shaping The Medical Industry, September 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
Valeant OTC Strategy Leverages “Relationships With Doctors”
The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.
Valeant OTC Strategy Leverages “Relationships With Doctors”
The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.
Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice